Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

High-Affinity Internalizing Human scFv-Fc Antibody for Targeting FGFR1-Overexpressing Lung Cancer
Aleksandra Sokołowska-Wędzina, Grzegorz Chodaczek, Julia Chudzian, et al.
Molecular Cancer Research (2017) Vol. 15, Iss. 8, pp. 1040-1050
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

Kinase-targeted cancer therapies: progress, challenges and future directions
Khushwant S. Bhullar, Naiara Orrego Lagarón, Eileen McGowan, et al.
Molecular Cancer (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 1064
Fibroblast growth factor receptors as treatment targets in clinical oncology
Masaru Katoh
Nature Reviews Clinical Oncology (2018) Vol. 16, Iss. 2, pp. 105-122
Closed Access | Times Cited: 301
Targeting Cellular Trafficking of Fibroblast Growth Factor Receptors as a Strategy for Selective Cancer Treatment
Natalia Porębska, Marta Latko, Marika Kucińska, et al.
Journal of Clinical Medicine (2018) Vol. 8, Iss. 1, pp. 7-7
Open Access | Times Cited: 82
Multivalent protein-drug conjugates – An emerging strategy for the upgraded precision and efficiency of drug delivery to cancer cells
Natalia Porębska, Krzysztof Ciura, Aleksandra Chorążewska, et al.
Biotechnology Advances (2023) Vol. 67, pp. 108213-108213
Open Access | Times Cited: 19
Protein liposomes-mediated targeted acetylcholinesterase gene delivery for effective liver cancer therapy
Kai Wang, Fusheng Shang, Dagui Chen, et al.
Journal of Nanobiotechnology (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 36
High Affinity Promotes Internalization of Engineered Antibodies Targeting FGFR1
Łukasz Opaliński, Jakub Szymczyk, Martyna Szczepara, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 5, pp. 1435-1435
Open Access | Times Cited: 28
FGF2 Dual Warhead Conjugate with Monomethyl Auristatin E and α-Amanitin Displays a Cytotoxic Effect towards Cancer Cells Overproducing FGF Receptor 1
K. Świderska, Anna Szlachcic, Łukasz Opaliński, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 7, pp. 2098-2098
Open Access | Times Cited: 28
Recent Advancements in Receptor Layer Engineering for Applications in SPR-Based Immunodiagnostics
Marcin Drozd, Sylwia Karoń, Elżbieta Malinowska
Sensors (2021) Vol. 21, Iss. 11, pp. 3781-3781
Open Access | Times Cited: 23
Generation of high-affinity, internalizing anti-FGFR2 single-chain variable antibody fragment fused with Fc for targeting gastrointestinal cancers
Aleksandra Borek, Aleksandra Sokołowska-Wędzina, Grzegorz Chodaczek, et al.
PLoS ONE (2018) Vol. 13, Iss. 2, pp. e0192194-e0192194
Open Access | Times Cited: 24
FGFR1 clustering with engineered tetravalent antibody improves the efficiency and modifies the mechanism of receptor internalization
Marta Poźniak, Aleksandra Sokołowska-Wędzina, Kamil Jastrzębski, et al.
Molecular Oncology (2020) Vol. 14, Iss. 9, pp. 1998-2021
Open Access | Times Cited: 21
Novel Method for Preparation of Site-Specific, Stoichiometric-Controlled Dual Warhead Conjugate of FGF2 via Dimerization Employing Sortase A-Mediated Ligation
Mateusz Adam Krzyścik, Łukasz Opaliński, Jacek Otlewski
Molecular Pharmaceutics (2019) Vol. 16, Iss. 8, pp. 3588-3599
Closed Access | Times Cited: 22
Identification of a peptide antagonist of the FGF1–FGFR1 signaling axis by phage display selection
Magdalena Lipok, Anna Szlachcic, Kinga Kindela, et al.
FEBS Open Bio (2019) Vol. 9, Iss. 5, pp. 914-924
Open Access | Times Cited: 20
The cytotoxic conjugate of highly internalizing tetravalent antibody for targeting FGFR1-overproducing cancer cells
Marta Poźniak, Natalia Porębska, Mateusz Adam Krzyścik, et al.
Molecular Medicine (2021) Vol. 27, Iss. 1
Open Access | Times Cited: 16
Drug Conjugation via Maleimide–Thiol Chemistry Does Not Affect Targeting Properties of Cysteine-Containing Anti-FGFR1 Peptibodies
Karolina Jendryczko, Jakub Rzeszótko, Mateusz Adam Krzyścik, et al.
Molecular Pharmaceutics (2022) Vol. 19, Iss. 5, pp. 1422-1433
Open Access | Times Cited: 12
HaloTag display enables quantitative single‐particle characterisation and functionalisation of engineered extracellular vesicles
Roxana E. Mitrut, Devin M. Stranford, Beth N. DiBiase, et al.
Journal of Extracellular Vesicles (2024) Vol. 13, Iss. 7
Open Access | Times Cited: 2
Specific Inhibition of Fibroblast Growth Factor Receptor 1 Signaling by a DNA aptamer
Vladimira Zlinska, Zuzana Feketová, Aleksandra Czyrek, et al.
Molecular Therapy — Nucleic Acids (2024) Vol. 36, Iss. 1, pp. 102405-102405
Open Access | Times Cited: 2
Effects of variable domain orientation on anti‐HER2 single‐chain variable fragment antibody expressed in the Escherichia coli cytoplasm
İlkay Koçer, Emily C. Cox, Matthew P. DeLisa, et al.
Biotechnology Progress (2020) Vol. 37, Iss. 2
Open Access | Times Cited: 14
Dissecting biological activities of fibroblast growth factor receptors by the coiled-coil-mediated oligomerization of FGF1
Natalia Porębska, Marta Poźniak, Mateusz Adam Krzyścik, et al.
International Journal of Biological Macromolecules (2021) Vol. 180, pp. 470-483
Open Access | Times Cited: 12
The autoinhibitory function of D1 domain of FGFR1 goes beyond the inhibition of ligand binding
Łukasz Opaliński, Martyna Szczepara, Aleksandra Sokołowska-Wędzina, et al.
The International Journal of Biochemistry & Cell Biology (2017) Vol. 89, pp. 193-198
Closed Access | Times Cited: 13
Modular self-assembly system for development of oligomeric, highly internalizing and potent cytotoxic conjugates targeting fibroblast growth factor receptors
Marta Poźniak, Natalia Porębska, Kamil Jastrzębski, et al.
Journal of Biomedical Science (2021) Vol. 28, Iss. 1
Open Access | Times Cited: 11
Intrinsically Fluorescent Oligomeric Cytotoxic Conjugates Toxic for FGFR1-Overproducing Cancers
Natalia Porębska, Agata Knapik, Marta Poźniak, et al.
Biomacromolecules (2021) Vol. 22, Iss. 12, pp. 5349-5362
Open Access | Times Cited: 11
Pharmacological and Biological Targeting of FGFR1 in Cancer
Shuai Fan, Yuxin Chen, Wenyu Wang, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 11, pp. 13131-13150
Open Access | Times Cited: 1
Specific Antibody Fragment Ligand Traps Blocking FGF1 Activity
Julia Chudzian, Anna Szlachcic, Małgorzata Zakrzewska, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 9, pp. 2470-2470
Open Access | Times Cited: 10
Recent progress in antitumor functions of the intracellular antibodies
Yunfeng Lin, Zhuo Chen, Chaohua Hu, et al.
Drug Discovery Today (2020) Vol. 25, Iss. 6, pp. 1109-1120
Closed Access | Times Cited: 10
Site-Specific, Stoichiometric-Controlled, PEGylated Conjugates of Fibroblast Growth Factor 2 (FGF2) with Hydrophilic Auristatin Y for Highly Selective Killing of Cancer Cells Overproducing Fibroblast Growth Factor Receptor 1 (FGFR1)
Mateusz Adam Krzyścik, Małgorzata Zakrzewska, Jacek Otlewski
Molecular Pharmaceutics (2020) Vol. 17, Iss. 7, pp. 2734-2748
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top